Fluid Biotech Inc.

6 enregistrements totalisant 611,036.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.

Intégrer ce graphique

Par ministère

Enregistrements

Western Economic Diversification Canada | Diversification de l'économie de l'Ouest Canada
Regional Economic Growth through Innovation
EF 2020-2021
Canada

Support for Fluid Biotech Inc. to continue operations during the COVID-19 pandemic

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2020-2021
Canada

For this IRAP project proposal, we will leverage our recently awarded MITACS funding to complete research and development studies on the absorption and flow diversion characteristics of our novel self...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Contributions to Firms
EF 2019-2020
Canada

Fluid Biotech is developing a bioabsorbable flow-diverting dissolving intravascular stent as an innovative way to treat patients with brain aneurysms. This project will result in the validation of med...

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Innovation Assistance Program
EF 2020-2021
Canada

The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.

National Research Council Canada | Conseil national de recherches Canada
Innovation Assistance Program
EF 2020-2021
Canada

The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.

National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program – Innovation Assistance Program
EF 2020-2021
Canada

The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.